Molecular Dynamics Simulation and Free Energy Landscape Analysis of Next-Generation KRAS G12D Inhibitors
DOI:
https://doi.org/10.5281/zenodo.22664633Keywords:
KRAS G12D, molecular dynamics, free energy landscape, MRTX1133, switch I/II conformational dynamicsAbstract
Background: MRTX1133 and the family of noncovalent, salt-bridge-forming chemotypes that followed it have turned KRAS G12D
from a textbook 'undruggable' target into an active medicinal chemistry problem, but the biophysical reasoning behind why these
molecules work, and why closely related analogues sometimes fail, lives almost entirely in the molecular dynamics (MD) and free
energy literature rather than in static crystal structures.
Objective: This review reads that literature specifically for its methodology and mechanistic claims about switch I/switch II
conformational behaviour, deliberately taking a distinct angle from a companion virtual-screening-focused review published
previously in this journal.
Scope: We examine force-field and simulation protocol choices used across KRAS G12D MD studies, the application of
MM-GBSA/MM-PBSA, alchemical free energy perturbation, umbrella sampling, and metadynamics to G12D-directed binders,
Markov state model reconstructions of MRTX1133 binding pathways, comparative free energy landscapes across G12 mutants, and
the still-thin literature on resistance-mutation dynamics.
Conclusions: Across heterogeneous force fields, simulation lengths, and free energy estimators, a broadly consistent physical picture
emerges in which G12D substitution destabilizes the closed switch conformation enough to expose a transient, druggable pocket
that MRTX1133-class chemistry locks via an Asp12 salt bridge network. Quantitative free energy estimates disagree considerably
between studies, alchemical FEP remains underused relative to its apparent suitability for this scaffold, and atomistic simulation of
resistance-associated substitutions lags well behind the discovery-side literature, representing the most consequential gap for
future work.
References
Prakash P, Gorfe AA (2014) Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras. Molecular Simulation, 40(10-11):839-847, DOI:10.1080/08927022.2014.895000.
Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, Hallin J, Laguer J, Lawson JD, Medwid J, Newhouse B, Nguyen P, O'Leary JM, Olson P, Pajk S, Rahbaek L, Rodriguez M, Smith CR, Tang TP, Thomas NC, Vanderpool D, Vigers GP, Christensen JG, Marx MA (2022) Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. Journal of Medicinal Chemistry, 65(4):3123-3133, DOI:10.1021/acs.jmedchem.1c01688.
Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, Lawson JD, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG (2022) Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine, 28(10):2171-2182, DOI:10.1038/s41591-022-02007-7.
Grant BJ, Gorfe AA, McCammon JA (2009) Ras Conformational Switching: Simulating Nucleotide-Dependent Conformational Transitions with Accelerated Molecular Dynamics. PLoS Computational Biology, 5(3):e1000325, DOI:10.1371/journal.pcbi.1000325.
Chen J, Zhang S, Zeng Q, Wang W, Zhang Q, Liu X (2022) Free Energy Profiles Relating With Conformational Transition of the Switch Domains Induced by G12 Mutations in GTP-Bound KRAS. Frontiers in Molecular Biosciences, 9:912518, DOI:10.3389/fmolb.2022.912518.
Hu Z, Sha Z, Marti J, Guo SJ, Tao SC (2026) Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets. JACS Au, 6(2):830-846, DOI:10.1021/jacsau.5c01097.
Akkapeddi P, Hattori T, Khan I, Glasser E, Koide A, Ketavarapu G, Whaby M, Zuberi M, Teng KW, Lefler J, Maso L, Bang I, Ostrowski MC, O'Bryan JP, Koide S (2023) Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors. Proceedings of the National Academy of Sciences, 120(28):e2302485120, DOI:10.1073/pnas.2302485120.
Abraham MJ, Murtola T, Schulz R, Pall S, Smith JC, Hess B, Lindahl E (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2:19-25, DOI:10.1016/j.softx.2015.06.001.
Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015) ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8):3696-3713, DOI:10.1021/acs.jctc.5b00255.
Huang J, MacKerell AD Jr (2013) CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. Journal of Computational Chemistry, 34(25):2135-2145, DOI:10.1002/jcc.23354.
Liang F, Kang Z, Sun X, Chen J, Duan X, He H, Cheng J (2023) Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study. Journal of Computer-Aided Molecular Design, 37(3):157-166, DOI:10.1007/s10822-023-00498-1.
Tu G, Gong Y, Yao X, Liu Q, Xue W, Zhang R (2024) Pathways and mechanism of MRTX1133 binding to KRAS G12D elucidated by molecular dynamics simulations and Markov state models. International Journal of Biological Macromolecules, 274:133374, DOI:10.1016/j.ijbiomac.2024.133374.
Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5):449-461, DOI:10.1517/17460441.2015.1032936.
Wang L, Wu Y, Deng Y, Kim B, Pierce L, Krilov G, Lupyan D, Robinson S, Dahlgren MK, Greenwood J, Romero DL, Masse C, Knight JL, Steinbrecher T, Beuming T, Damm W, Harder E, Sherman W, Brewer M, Wester R, Murcko M, Wang L, Berne BJ, Friesner RA, Abel R (2015) Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field. Journal of the American Chemical Society, 137(7):2695-2703, DOI:10.1021/ja512751q.
Awasthi S, Kapil V, Nair NN (2016) Sampling free energy surfaces as slices by combining umbrella sampling and metadynamics. Journal of Computational Chemistry, 37(16):1413-1424, DOI:10.1002/jcc.24349.
Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, Shang Y, Zhang L, Li X, Zhang Y, Du Y, Chen CC, Guo RT, Zhang Y (2022) KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discovery, 8(1):5, DOI:10.1038/s41421-021-00368-w.
Ancy I, Penislusshiyan S, Ameen F, Chitra L (2024) Microsecond Molecular Dynamics Simulation to Gain Insight Into the Binding of MRTX1133 and Trametinib With KRASG12D Mutant Protein for Drug Repurposing. Journal of Molecular Recognition, 37(6):e3103, DOI:10.1002/jmr.3103.
Alamri A, Mir SA, Khan S, Ahmad I, Razzokov J, Nayak B (2026) Exploring the GDP binding to KRas WT, G12C, G12D, G12R, and G12V and bound with MRTX1133 using steered molecular dynamics. European Biophysics Journal, 55(1):79-88, DOI:10.1007/s00249-026-01817-8.
Du Z, Tu G, Gong Y, Fu X, Wu Q, Long G (2024) Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations. Molecules, 29(6):1229, DOI:10.3390/molecules29061229.
